Literature DB >> 29500633

Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy.

Aglaia Domouchtsidou1, Vahé Barsegian2, Stefan P Mueller3, Jan Best4, Judith Ertle4, Sotiria Bedreli4, Peter A Horn1, Andreas Bockisch3, Monika Lindemann5.   

Abstract

The purpose of our study was to assess the immune function of patients with inoperable hepatic malignancies after treatment with selective internal radiotherapy (SIRT) and to identify possible correlations with clinical parameters. In 25 patients receiving SIRT lymphocyte proliferation and the production of pro- and anti-inflammatory cytokines (interferon-γ and interleukin-10) after stimulation with mitogens and microbial antigens were tested prior to therapy, directly after therapy (day 1) and at day 2, 7 and 28 post therapy using the lymphocyte transformation test and enzyme-linked immunospot assays. Absolute counts and percentages of leukocyte and lymphocyte subsets were determined by flow cytometry. The most prominent finding was an immediate and significant (p < 0.05) decrease of lymphocyte proliferation and interferon-γ production directly after therapy which lasted until day 28 and was stronger upon stimulation with microbial antigens than with mitogens. Moreover, lymphopenia was revealed, affecting all lymphocyte subsets (CD3+, CD4+, CD8+ T cells, CD4+ CD8+ T cells, B cells and NK cells). SIRT led to a reduction in the percentage of activated HLA-DR+ monocytes and of CD45R0+ memory T cells. Higher radiation activity, the presence of liver cirrhosis, chronic kidney disease, diabetes mellitus and metastases were unfavorable factors for immunocompetence, while a better Eastern Cooperative Oncology Group performance status was associated with stronger immunological reactions. In conclusion, SIRT leads to severe impairment of cellular in vitro immune responses. Further studies are needed to assess a potential clinical impact.

Entities:  

Keywords:  ELISpot; Flow cytometry; Hepatic malignancy; Interferon-γ; Lymphocyte proliferation; Selective internal radiotherapy

Mesh:

Substances:

Year:  2018        PMID: 29500633     DOI: 10.1007/s00262-018-2141-0

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  8 in total

Review 1.  Combined locoregional-immunotherapy for liver cancer.

Authors:  Tim F Greten; Michal Mauda-Havakuk; Bernd Heinrich; Firouzeh Korangy; Bradford J Wood
Journal:  J Hepatol       Date:  2019-02-07       Impact factor: 25.083

2.  Lymphocytes, Neutrophils and the Response to Selective Internal Radiation Therapy: More Questions than Answers Yet.

Authors:  Manuel de la Torre-Aláez; Bruno Sangro
Journal:  Cardiovasc Intervent Radiol       Date:  2020-06-17       Impact factor: 2.740

Review 3.  Implications of Immunotherapy in Hepatobiliary Tumors.

Authors:  Aline Gottlieb; Jan Best; Ali Canbay
Journal:  Visc Med       Date:  2019-02-08

4.  Dynamic Lymphocyte Changes Following Transarterial Radioembolization: Association with Normal Liver Dose and Effect on Overall Survival.

Authors:  Shamar Young; Ranjan Ragulojan; Ting Chen; Joshua Owen; Donna D'souza; Tina Sanghvi; Jafar Golzarian; Siobhan Flanagan
Journal:  J Hepatocell Carcinoma       Date:  2022-02-04

Review 5.  Severe Radiation-Induced Lymphopenia Affects the Outcomes of Esophageal Cancer: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Dongjun Dai; Qiaoying Tian; Genhua Yu; Yongjie Shui; Hao Jiang; Qichun Wei
Journal:  Cancers (Basel)       Date:  2022-06-20       Impact factor: 6.575

6.  Lymphopenia During Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma: Association with Dosimetric Parameters and Patient Outcomes.

Authors:  Hui Xu; Maosheng Lin; Yingying Hu; Li Zhang; Qiaoqiao Li; Jinhan Zhu; Shi Wang; Mian Xi
Journal:  Oncologist       Date:  2020-10-06

Review 7.  Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response.

Authors:  Elisa C Toffoli; Abdolkarim Sheikhi; Yannick D Höppner; Pita de Kok; Mahsa Yazdanpanah-Samani; Jan Spanholtz; Henk M W Verheul; Hans J van der Vliet; Tanja D de Gruijl
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

8.  Prognostic value of absolute lymphocyte count in patients with advanced esophageal cancer treated with immunotherapy: a retrospective analysis.

Authors:  Qi Zhao; Yanping Bi; Jiao Xue; Yandong Liu; Jiaxing Zhu; Songbing Qin
Journal:  Ann Transl Med       Date:  2022-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.